Migration Biotherapeutics

• About Migration Biotherapeutics
  Migration Biotherapeutics is a UK-based biotechnology company focused on revolutionising the management of invasive brain cancers, specifically Glioblastoma Multiforme (GBM). Our flagship innovation, the ALIGHT device, is a first-in-class "ecological trap" designed to manage tumor recurrence by exploiting the natural migratory instincts of cancer cells.

  Our Technology:
  The ALIGHT Device Unlike traditional pharmacological approaches that often fail due to the blood-brain barrier and systemic toxicity, ALIGHT utilises electrospun PCL nanofibers to provide a physical "decoy" for invasive GBM cells. By mimicking the topography of the brain’s white matter tracts, the device utilizes contact guidance to redirect migrating cells away from healthy tissue and into a retention matrix where they can be focalised and managed. This non-radioactive, non-pharmacological approach offers a safer, simpler surgical profile.

  Partnership & Collaboration Goals
  We are seeking to join or form consortia for the 2026 Horizon Europe Cancer Mission and Cluster Health calls. We are specifically looking for high-level expertise from research organisations in the following areas:

  • In Silico Computational Modelling: To develop "Digital Twin" models of our device’s physical steering mechanisms, helping to accelerate R&D and de-risk clinical translation through predictive performance data.

  • 3D Cancer Organoid Models: To enhance our in vitro validation using high-fidelity organoid models that accurately replicate the complex tumor microenvironment of the human brain.

  • Advanced Bio-fabrication: Groups with specialised expertise in medical applications of electrospinning or innovative bio-ink formulations for neurological implants.

Why Partner with Migration Bio?
Migration Biotherapeutics offers a unique industrial-academic bridge. We provide a validated, innovative platform technology (ALIGHT) with a strong commercial potential. As a start-up, we bring agility, and a deep commitment to delivering transformative patient outcomes in neuro-oncology.